Edition:
United Kingdom

Genfit SA (GNFT.PA)

GNFT.PA on Paris Stock Exchange

21.46EUR
25 Mar 2019
Change (% chg)

€-1.00 (-4.45%)
Prev Close
€22.46
Open
€22.04
Day's High
€22.34
Day's Low
€21.40
Volume
254,521
Avg. Vol
196,544
52-wk High
€25.88
52-wk Low
€15.54

Latest Key Developments (Source: Significant Developments)

Genfit SA Sees U.S. IPO Of Up To 5.0 Mln Ordinary Shares
Thursday, 14 Mar 2019 

March 14 (Reuters) - Genfit SA ::GENFIT SA SEES U.S. IPO OF UP TO 5.0 MILLION ORDINARY SHARES - SEC FILING.  Full Article

Genfit Announces FDA Protocol Clearance For Phase 2 Clinical Trial Of Elafibranor In Pediatric NASH
Monday, 11 Mar 2019 

March 11 (Reuters) - GENFIT SA ::REG-GENFIT ANNOUNCES FDA PROTOCOL CLEARANCE FOR PHASE 2 CLINICAL TRIAL OF ELAFIBRANOR IN PEDIATRIC NASH.FDA ACCEPTS STUDY PROTOCOL, PROVIDING GREEN LIGHT FOR GENFIT TO INITIATE PHASE 2 CLINICAL TRIAL IN PEDIATRIC NASH.ELAFIBRANOR, THE FIRST MOLECULE WITH POSITIVE RESULTS ON REGISTRATIONAL ENDPOINT IN PHASE 2B CLINICAL TRIAL IN ADULT NASH TO BE EVALUATED IN PEDIATRIC NASH.12-WEEK RANDOMIZED TRIAL OF 20 PEDIATRIC PATIENTS TO BE INITIATED AT U.S. CLINICAL CENTERS SPECIALIZING IN NASH PEDIATRICS.  Full Article

Genfit Reports FY Revenues And Other Income Of 7.5 Million Euros Versus 6.9 Million Euros
Tuesday, 5 Feb 2019 

Feb 4 (Reuters) - Genfit SA ::FY REVENUES AND OTHER INCOME OF 7.5 MILLION EUROS VERSUS 6.9 MILLION EUROS.FY NET LOSS 79.5 MILLION EUROS VERSUS 55.7 MILLION EUROS.FY BASIC LOSS PER SHARE $2.55.CASH POSITION OF EUR 207.2 MILLION AS OF DECEMBER 31, 2018, COMPARED TO EUR 273.8 MILLION AS OF DECEMBER 31, 2017.FY2018 REVENUE VIEW EUR 5.9 MILLION -- REFINITIV IBES DATA.FY2018 EARNINGS PER SHARE VIEW EUR -2.13 -- REFINITIV IBES DATA.  Full Article

Genfit Plans To Conduct Registered Public Offering In The U.S
Monday, 19 Nov 2018 

Nov 19 (Reuters) - GENFIT SA ::REG-GENFIT ANNOUNCES PLANS TO CONDUCT REGISTERED PUBLIC OFFERING IN THE UNITED STATES.SIMULTANEOUSLY WITH PUBLIC OFFERING IN UNITED STATES, GENFIT PLANS TO CONDUCT A PRIVATE PLACEMENT OF ITS ORDINARY SHARES OUTSIDE OF US.TIMING, NUMBER OF NEW ORDINARY SHARES AND ADSS TO BE ISSUED AND PRICE OF ORDINARY SHARES AND ADSS TO BE ISSUED HAVE NOT YET BEEN DETERMINED.HAS CONFIDENTIALLY SUBMITTED A DRAFT REGISTRATION STATEMENT ON FORM F-1 TO U.S. SEC.  Full Article

Genfit Cash And Cash Equivalents Up At 219.9 Million Euros At September 30
Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - GENFIT SA ::REVENUES FOR FIRST NINE MONTHS OF 2018 OF EUR 68 THOUSAND.AT JUNE 30, 2018, CASH AND CASH EQUIVALENTS TOTALED €238 MILLION..AT SEPTEMBER 30, 2018, CASH AND CASH EQUIVALENTS AMOUNTED TO €219.9 MILLION COMPARED WITH €113.8 MILLION ONE YEAR EARLIER..  Full Article

Genfit H1 Revenue Up At 5.1 Million Euros
Monday, 24 Sep 2018 

Sept 24 (Reuters) - GENFIT SA ::H1 OPERATING LOSS EUR 31.6 MILLION VERSUS LOSS OF EUR 22.4 MILLION YEAR AGO.H1 NET LOSS EUR 34.5 MILLION VERSUS LOSS OF EUR 22.6 MILLION YEAR AGO.H1 REVENUE EUR 5.1 MILLION VERSUS EUR 4.7 MILLION YEAR AGO.CASH AND CASH EQUIVALENTS OF EUR 238 MILLION AT JUNE 30, 2018 (EUR 273.8 MILLION AT DECEMBER 31, 2017)..  Full Article

Genfit Announces Positive Elafibranor Preclinical Study Results
Wednesday, 27 Jun 2018 

June 27 (Reuters) - GENFIT SA ::NEW PRECLINICAL DATA SHOWS ELAFIBRANOR INHIBITS DEVELOPMENT OF NAFLD/NASH-RELATED CANCER.ELAFIBRANOR ADMINISTRATION PREVENTED LIVER TUMOR DEVELOPMENT IN NAFLD/NASH DISEASE MODELS.ELAFIBRANOR SHOWED DIRECT CYTOSTATIC PROPERTIES ON A LARGE SELECTION OF HUMAN TUMOR CELL-LINES.  Full Article

Genfit Announces Positive Outcome From The Safety Review By The DSMB
Monday, 23 Apr 2018 

April 23 (Reuters) - GENFIT SA ::REG-GENFIT : POSITIVE OUTCOME FROM THE 24-MONTH PRE-PLANNED SAFETY REVIEW BY THE DSMB, IN RESOLVE-IT PHASE 3 CLINICAL TRIAL WITH ELAFIBRANOR.DATA SAFETY MONITORING BOARD (DSMB) WHICH RECOMMENDED CONTINUATION OF TRIAL WITHOUT ANY MODIFICATIONS.POSITIVE OUTCOME, CONFIRMS GOOD SAFETY PROFILE OF ELAFIBRANOR.  Full Article

Genfit: Official Launch Of NASH Pediatric Program In US
Tuesday, 23 Jan 2018 

Jan 23 (Reuters) - GENFIT SA ::REG-GENFIT: OFFICIAL LAUNCH OF THE NASH PEDIATRIC PROGRAM, FOLLOWING PIP AND PSP AGREEMENT BY EMA AND FDA.‍FDA AGREES WITH ELAFIBRANOR'S INITIAL PSP FOR LAUNCH OF NASH PEDIATRIC CLINICAL TRIAL IN US.‍PHASE 2B DATA SUPPORTIVE OF ELAFIBRANOR'S POTENTIAL BENEFIT IN NASH PEDIATRIC POPULATION​.PSP AGREEMENT BY FDA CONSISTENT WITH PIP (PEDIATRIC INVESTIGATION PLAN) AGREEMENT BY EMA (EUROPEAN MEDICINES AGENCY).‍DOSE RANGING STUDY TO START IN COMING WEEKS, ON YOUNG NASH PATIENTS LIVING IN US (8-17 YEARS OLD)​.  Full Article

Genfit announces positive outcome of DSMB safety review
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - GENFIT SA ::REG-GENFIT: POSITIVE OUTCOME FROM THE 18-MONTH PRE-PLANNED SAFETY REVIEW BY THE DSMB, IN RESOLVE-IT PHASE 3 CLINICAL TRIAL WITH ELAFIBRANOR.‍SAFETY DATA REVIEWED BY DSMB WHICH RECOMMENDED CONTINUATION OF TRIAL WITHOUT ANY MODIFICATIONS​.‍POSITIVE OUTCOME OF REVIEW ALLOWS GENFIT TO ACTIVELY PURSUE ITS EFFORT IN ENROLLING PATIENTS AND CONTINUATION OF RESOLVE-IT TRIAL​.‍POSITIVE OUTCOME CONFIRMS GOOD SAFETY PROFILE OF ELAFIBRANOR​.  Full Article

Photo

Novartis, Pfizer join forces on potentially lucrative fatty liver disease

ZURICH/NEW YORK Novartis AG and Pfizer Inc are teaming up to develop treatments for a liver disease many drug companies believe will become a hugely lucrative market, as it is tied to the obesity and diabetes epidemics.